Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7546 to 7560 of 8314 results

  1. NephroCheck test to help assess the risk of acute kidney injury in critically ill patients (MIB156)

    This medtech innovation briefing has been updated and replaced by NICE HealthTech guidance 544.

  2. EarlyCDT-Lung for cancer risk classification of indeterminate pulmonary nodules (MIB209)

    This advice has been updated and replaced by NICE healthtech guidance 611.

  3. FibroScan for assessing liver fibrosis and cirrhosis in primary care (MIB216)

    This advice has been updated and replaced by NICE healthtech guidance 682.

  4. Promonitor for monitoring response to biologics in rheumatoid arthritis (MIB126)

    This advice has been replaced by NICE HealthTech guidance 521.

  5. Point-of-care creatinine tests before contrast-enhanced imaging (MIB136)

    This advice has been replaced by NICE HealthTech guidance 530.

  6. LiverMultiScan for liver disease (MIB181)

    This advice has been updated and replaced by NICE healthtech guidance 655.

  7. QbTest for the assessment of attention deficit hyperactivity disorder (ADHD) (MIB318)

    This advice has been updated and replaced by NICE healthtech guidance 729.

  8. The BCM – Body Composition Monitor for managing fluid in people having dialysis (MIB41)

    This advice has been updated and replaced by NICE guidance HTG441 

  9. Personal KinetiGraph for remote clinical management of Parkinson's disease (MIB258)

    This advice has been updated and replaced by NICE healthtech guidance 657.

  10. RapidAI for analysing CT/MRI brain scans in people with suspected acute stroke (MIB262)

    This advice has been updated and replaced by NICE healthtech guidance 708.

  11. Autologous haematopoietic stem cell transplantation for treating multiple sclerosis [ID1111]

    Discontinued Reference number: GID-TA10306

  12. Betibeglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID968]

    Discontinued Reference number: GID-TA10334

  13. Durvalumab with tremelimumab for untreated PD-L1-positive urothelial bladder cancer [ID1335]

    Discontinued Reference number: GID-TA10315

  14. Veliparib in combination for treating BRCA-positive, HER2-negative breast advanced cancer [ID1404]

    Discontinued Reference number: GID-TA10327